In Brief: Centocor
This article was originally published in The Gray Sheet
Executive Summary
Centocor: Gains FDA go-ahead to market two new diagnostic tests: the Captia syphilis-G, a microtiter-based enzyme immunoassay for use in blood banks or plasma centers to screen for Treponema pallidum antibodies, and the CA 125 II cancer assay for use as "an aid in the detection of residual epithelial ovarian cancer," according to the company. The second-generation CA 125 test "enhances low-end sensitivity." The Captia was cleared via 510(k) while the CA 125 II assay was approved by PMA supplement...
You may also be interested in...
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.
Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win
Topline results from two studies in obstructive sleep apnea among obese adults showed efficacy crossing the 50% threshold that physicians have called clinically meaningful.